Claim 1: A solid oral immediate release dosage form, characterized in that it comprises a plurality of particles, wherein each particle comprises: i) an active agent； and (ii) a material that is sensitive to acidic pH； where the dosage form releases at least about 70% of the active agent within 45 minutes measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml of 0.1 N HCl at 37 ° C. Claim 26: The solid oral immediate release dosage form of claim 3,It is characterized by a viscosity of a dosage form mixed in 0.5 to 10 ml of distilled water that prevents the active agent from being absorbed in the system, or reduces the ability of the active agent to be absorbed by the system when it is carried out through a parent or nasal. Claim 40: immediate release of the solid oral dose form of claim 6, characterized by the first active agent being a non opioid analgesic and the second active agent being an opioid preparation. Claim 42: immediate release of a solid oral dose form of any one of claims 1, 2, 37 or 38,characterized in that it also comprises an aversive agent. Claim 70: A process for preparing a solid oral immediate release dosage form, characterized in that it comprises: (i) preparing a plurality of particles, wherein each particle comprises an active agent and a material that is sensitive to acidic pH； and (ii) dispersing the plurality of particles in a matrix； where the dosage form releases at least about 70% of the active agent within 45 minutes measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml of 0.1 N HCl at 37 ° C.Reivindicación 1: Una forma de dosificación oral sólida de liberación inmediata, caracterizada porque comprende una pluralidad de partículas, donde cada partícula comprende: i) un agente activo； y (ii) un material que es sensible al pH ácido； donde la forma de dosificación libera al menos alrededor de 70% del agente activo dentro de 45 minutos medido mediante disolución in-vitro en un Apa
